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BACKGROUND: Importance of androgen receptor (AR) as an independent prognosticmarker in Pakistani womenwith
breast cancer (BCa) remains unexplored. Our aim was to identify the expression and potential prognostic value of AR,
its upstream regulator (pAkt) and target gene (pPTEN) in invasive BCa. METHODS: This study used a cohort of 200
Pakistani womenwith invasive BCa diagnosed during 2002-2011. Expression of AR, pAkt and pPTENwas determined
on formalin fixed paraffin embedded tissue sections by immunohistochemistry. The association of AR, pAkt and
pPTEN with clinicopathological parameters was determined. Survival analyses were undertaken on patients with
≥5 years of follow-up (n = 82). RESULTS: Expression of AR, pAkt and pPTEN was observed in 47.5%, 81.3% and
50.6% of patients, respectively. AR-expressing tumorswere low or intermediate in grade (P b .001) and expressed ER
(P = .002) and PR (P = .001). Patientswith AR+ tumors had significantly higher OS (MeanOS = 10.2 ± 0.465 years)
compared to patients with AR− tumors (Mean OS = 5.8 ± 0.348 years) (P = .047). Furthermore, AR-positivity was
associated with improved OS in patients receiving endocrine therapy (P = .020). Patients with AR+ /pAkt+ /pPTEN−
tumors, had increased OS (Mean OS = 7.1 ± 0.535 years) compared to patients with AR−/pAkt+/pPTEN− tumors
(Mean OS = 5.1 ± 0.738 years). CONCLUSION: AR-expressing tumors are frequently characterized by low or
intermediate grade tumors, expressingERandPR. In addition, expression of AR, pAkt and pPTEN, could be considered
in prognostication of patients with invasive BCa.
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Breast cancer (BCa) is the most common malignancy among women
around the globe, and it is recognized to be the second most common
cause of death in women [1]. Its rate is rising rapidly in Asian women
and the developing world. According to the Surveillance, Epidemi-
ology, and End Results database, Asian Indian/Pakistani women
residing in the United States seem to have a higher frequency of BCa
particularly at a younger age (b40 years) compared to Caucasians [2].
The data from South Karachi, a pragmatic representative of the
population of Pakistan, revealed that BCa accounted for approxi-
mately one third of cancers in women [3].
Hormone receptors such as estrogen (ERs) and progesterone
receptors (PRs) play a seminal role in determining the treatment
strategy and prognosis of patients with BCa. In addition, human
epidermal growth factor receptor type 2 (HER2) has been found to beoverexpressed in a subset of invasive BCa and is associated with poor
prognosis [4,5]. According to Surveillance, Epidemiology and End
Results database, Asian Indian/Pakistani women residing in the
United States had more ER/PR-negative BCa (30.6%) compared to
Caucasians (21.8%) [2]. These data are similar to studies undertaken
on samples of BCa from women residing in Pakistan that showed thatA
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356 Androgen Receptor, pAkt, and pPTEN in Breast Cancer Sultana et al. Translational Oncology Vol. 7, No. 3, 201460% to 65% of the tumors expressed ER/PR [6,7]. Furthermore,
frequency of HER2 expression has also found to be higher in
Pakistani women with BCa (30%-39%) [6,8,9] in contrast to
Caucasians (25%-30%) [4,5].
Only a limited number of studies have evaluated the role of the
androgen receptor (AR), phosphorylated Akt (pAkt), and phosphory-
lated phosphatase and tensin homolog (pPTEN) as potential predictive
or prognostic markers compared to the large number of studies on ER,
PR, and HER2.
AR is a ligand-dependent transcription factor; its expression on BCa
is known to be linkedwith improved survival [10–12].Hu et al. assessed
AR status in a large (n = 1467) cohort of patients with BCa; they found
91% and 86% 5-year survival in patients with AR-positive and
AR-negative tumors, respectively [11], whereas other studies have not
found a similar association with survival [13,14]. AR expression has
been observed in approximately 40% to 80% of BCas [11,15–19].
Although a significant number of patients with BCa express AR, the
underlying molecular mechanisms of AR signaling pathway in BCa
biology have not been intensely studied, and the role of AR on survival
in patients with BCa needs further delineation.
Protein kinase B (more commonly referred as Akt) is a serine/threonine
kinase, which plays a role in BCa growth by promoting cell survival and
inhibiting cell death [20,21] and is being considered as a potential target
for BCa therapy [22,23], whereas PTEN, a well-recognized tumor
suppressor gene, negatively regulates Akt and has been shown to inhibit
BCa growth [24,25]. Nagata and colleagues reported loss of PTEN in
50% of patients with BCa [26]. AR has been shown to increase PTEN
expression by activating its promoter that in turn lowers Akt activity and
decreases cellular proliferation in BCa [27]. Wang et al. also reported that
AR increases PTEN expression and inhibits Akt phosphorylation in BCa
cells [28]. PTEN is a positive modulator, whereas Akt is a negative
modulator of AR transcriptional activity. The cross talk of AR signaling
with Akt and PTEN that may have clinical significance in the
development of BCa has not been well studied, though the expression
of Akt and PTEN in BCa tissue has been reported [29–31].
To our knowledge, to date, no studies have been undertaken
examining the expression of AR, active form of Akt (pAkt), and stable
form of PTEN (pPTEN) on BCa in a cohort of Pakistani women. In
this study, our aim was to determine the immunohistochemical
expression of AR, pAkt, and pPTEN in Pakistani women with
invasive BCa and their role as potential prognostic markers. We also
examined the significance of AR expression on patient's survival after
stratifying by ER, pAkt, and pPTEN status and endocrine treatment.
Materials and Methods
Patients and Setting
A total of 1103 patients were diagnosed with invasive BCa and treated
at the section of breast diseases, Aga Khan University Hospital (Karachi,
Pakistan), during 2002 to 2011. From a total of 1103 cases, 200 were
selected for this study on the basis of the following criteria: 1) availability
of formalin-fixed paraffin-embedded (FFPE) tissue blocks, 2) sufficient
representative area of primary tumor in FFPE blocks, and 3) complete
follow-up data. Demographical data, details of treatment regimen,
clinicopathologic parameters including tumor size and type, ER/PR/
HER2 status, grade, and lymph node status, and clinical follow-up were
obtained by reviewing medical records. To minimize the selection bias,
we compared the clinicopathologic characteristic between patients who
were selected for this study (n = 200) with those who were not selected(n = 903), and no statistically significant difference was found between
the two groups. All patients had previously consented for use of their
tissues and clinicopathologic data for research.
Five-micron serial sections were cut from FFPE BCa tissue blocks.
At least one section was stained with hematoxylin and eosin, assessed
by a pathologist, and compared to original report. The study was
approved by the Ethical Review Committee of the Aga Khan
University (2390-RO-ERC-12).
Survival analysis was performed on a subgroup of patients with
BCa who had follow-up of at least 5 years or more (n = 82). Patients
diagnosed during 2002 to 2008 and followed up until December
2013 or death were included for survival analysis. Overall survival
(OS) was calculated from the date of diagnosis to the date of last
follow-up or death due to any cause.
Immunohistochemical Expression of AR, pAkt, and pPTEN
Immunohistochemistry was performed on FFPE sections to assess
the expression of AR, pAkt, and pPTEN as described previously with
some modifications [32–34]. Dako REAL EnVision Detection
System, Peroxidase/DAB+, Rb/Mo (Dako, Glostrup, Denmark)
was used for immunohistochemical staining. Briefly, 5-μm serial
sections were cut from FFPE tissue onto Superfrost slides (Thermo
Scientific, Braunschweig, Germany). Sections were deparaffinized in
xylene (BDH, Poole, UK) and rehydrated in a graded series of ethanol
(Merck, Darmstadt, Germany). Heat-induced antigen retrieval was
performed in 10 mM citrate buffer (pH 6.0) for AR (1 hour), pAkt,
and pPTEN (30 minutes) in a boiling water bath (Grant Instruments
Ltd., Cambridge, UK). Endogenous peroxidase activity was blocked
by immersing slides in 0.3% vol/vol H2O2 at room temperature
(RT; 25°C) for 10 minutes. Next, anti-human AR antibody (mouse
monoclonal IgG, clone AR441; Dako, diluted 1:50) was applied for
4 hours at RT, and anti-human Ser473 pAkt1/2/3 (rabbit polyclonal
IgG; Santa Cruz Biotechnology, diluted 1:50) and Ser380/Thr382/383
pPTEN (rabbit polyclonal IgG; Santa Cruz Biotechnology (Santa
Cruz, CA), diluted 1:50) were applied for overnight at 4°C onto serial
tissue sections from each case. After three washes for 5 minutes
each in phosphate-buffered saline (pH7.4) (Gibco, Carlsbad, CA),
HRP-labeled secondary antibody was applied for 1 hour at RT. After
washing, substrate was added, and DAB was used for visualization.
Hematoxylin (BDH) was used for counterstaining, and images were
obtained using microscope (Olympus BX41, Tokyo, Japan, DP70
camera). Negative (primary antibody replaced by phosphate buffer
saline) and positive (a known BCa tissue section positive for AR,
pAkt, pPTEN) controls were included with each run. Our
experimental methodology including antigen retrieval, choice of the
antibody, and detection system was in concordance with previously
reported studies.
Scoring
Stained sections were scored by a pathologist who was masked
for patient’s clinicopathologic parameters and outcomes. Slides
were scored using Allred guidelines [35]. In brief, entire slide of
each sample was evaluated using Olympus BX41 microscope at
×100 and ×200 magnifications. First, proportion of positively
stained tumor cells (0, none; 1, b1/100; 2, 1/100 to 1/10; 3, 1/10
to 1/3; 4, 1/3 to 2/3; and 5, N2/3) was estimated. Next, an
intensity score that represented the average intensity of positive
tumor cells (1, weak; 2, intermediate; and 3, strong) was
estimated. The proportion and intensity scores were then added
Table 1. Relative Percentage of Expression of AR, pAkt, pPTEN, ER, PR, and HER2 from
Different Studies in Invasive BCa.
Marker Current Study (%) Other Studies in Pakistani Population (%) Caucasians (%)
AR 47.5 None 70-80 [11,36]
pAkt * 81.3 None 76-81 [30,34]
pPTEN ** 50.6 None 49-52 [31,37]
ER/PR 56 60-65 [6,7] 55-70 [38,39]
HER2 *** 24 30-39 [6,8,9] 25-30 [4,5]
AR, androgen receptor; pAkt, phosphorylated Akt; pPTEN, phosphorylated phosphatase and
tensin homolog; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
growth factor receptor type 2.
* n = 166.
** n = 162.
*** n = 192.
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for AR and cytoplasmic staining for pAkt and pPTEN with a total
score of ≥3 were considered positive.
Statistical Analysis
Frequencies of different markers including AR, pAkt, and pPTEN
with 95% confidence intervals (CIs) were generated for the expression
of these markers. Descriptive statistics was determined for continuous
(mean ± SE) and categorical (percentages) variables. The associations
of AR, pAkt, and pPTEN expression with demographical data,
details of treatment regimen, and clinicopathologic parameters like
tumor type, grade, size, status of lymph node, ER, PR, and HER2
were assessed by χ2 test if appropriate; otherwise, Fisher exact test
was applied. OS were computed using Kaplan-Meier method.
Means and SE of OS time were reported for clinicopathologicC
A
Figure 1. Immunohistochemical expression of AR, pAkt, and pPTE
(B) cytoplasmic pAkt, and (C) pPTEN protein expression in a tumor. Iparameters. The association of different survival times by these
markers was obtained using log-rank test. A P value b .05 (two
sided) was considered statistically significant. SPSS (version 18.0,
IBM Company, Chicago, IL) was used for all statistical analysis.
Results
Patients and Tumor Characteristics
Mean (±SE) age of patients at diagnosis was 54.8 (±10.5) years, of
which 39%were younger than 50 years. Most of the tumors (95.5%)
were ductal, followed by lobular (3%) and mucinous carcinomas
(1.5%). More than half of the tumors (56.5%) were of grade II,
54.5% of tumors were 2 to 5 cm in size, and 53.0% of the primary
tumors had no lymph node involvement at diagnosis. Among 121 cases
of ER-positive tumor, 115 (95%) patients received endocrine therapy.
Majority of them (89.5%) received tamoxifen as first option, whereas
the remainder (10.5%) received either Femara (Novartis, Basel,
Switzerland) or Arimidex (ICI Pakistan Ltd., Karachi, Pakistan).
Expression of AR, pAkt, and pPTEN
Expression of AR, pAkt, and pPTEN was observed in 47.5% (95%
CI = 40.6%-54.4%), 81.3% (95% CI = 75.4%-87.2%), and 50.6%
(95% CI = 42.9%-58.3%) of patients, respectively.
The percentage of tumors that expressed AR, pAkt, pPTEN, ER,
PR, and HER2 are shown in Table 1. AR expression was
predominantly found to be localized in the nuclei, whereas pAkt
and pPTEN were predominantly found to be localized in the
cytoplasm. Representative photomicrographs of AR, pAkt, and
pPTEN expression in tissue sections are shown in Figure 1.B
N in invasive breast carcinoma. (A) Heterogeneous nuclear AR,
mages are at ×200, and insights are at ×400 magnification.
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and pPTEN
Expression of AR was significantly associated with increasing age
N50 years (P = .040), low or intermediate grade (I and II) tumors
(P = .001), expression of ER (P = .002), PR (P = .001), and
therapeutic modalities including endocrine (P = .004) and chemo-
therapy (P = .015). There were no significant differences observed
between AR expression and tumor size, lymph node involvement,
HER2 status, tumor type, radiation therapy, and expression of pAkt
and pPTEN (Table 2).
Overall Survival
Survival analysis was performed on 82 patients who had been
followed for five or more years. A total of 16 deaths were reported
during this period. The mean OS time was 9.2 ± 0.41 years, and lost
to follow-up was 17% (n = 14) only.able 2. Association of AR Expression with Demographical, Clinicopathologic Parameters, pAkt,
nd pPTEN.
actor AR-Positive
n = 95 (47.5%)
AR-Negative
n = 105 (52.5%)
P Value
ge at diagnosis (years) .040 *
≤50 30 (38.5) 48 (61.5)
N50 65 (53.3) 57 (46.7)
umor size (n = 189) ** .400
T1 20 (46.5) 23 (53.5)
T2 56 (51.4) 53 (48.6)
T3 10 (34.5) 19 (65.5)
T4 3 (37.5) 5 (62.5)
ode involvement (n = 192) .287
N0 45 (42.5) 61 (57.5)
N1 27 (55.1) 22 (44.9)
N2 8 (42.1) 11 (57.9)
N3 11 (61.1) 7 (38.9)
rade (n = 197) b .001 *
I and II 71 (58.2) 51 (41.8)
III 23 (30.7) 52 (69.3)
umor type ** .097
Invasive ductal 88 (46.1) 103 (53.9)
Invasive lobular 4 (66.7) 2 (33.3)
Invasive mucinous 3 (100) 0 (0)
R .002 *
Positive 68(56.2) 53 (43.8)
Negative 27 (34.2) 52 (65.8)
R .001 *
Positive 67 (57.3) 50 (42.7)
Negative 28 33.7) 55 (66.3)
Akt (n = 166) .272
Positive 68 (50.4) 67 (49.6)
Negative 19 (61.3) 12 (38.7)
PTEN (n = 162) .341
Positive 40 (48.8) 42 (51.2)
Negative 45 (56.3) 35(43.8)
ER2 (n = 192) .740
Positive 24 (51.1) 23 (48.9)
Negative 70 (48.3) 75 (51.7)
adiotherapy .523
Yes 81 (48.5) 86 (51.5)
No 14 (42.4) 19 (57.6)
hemotherapy .015 *
Yes 64 (54.7) 53 (45.3)
No 31 (37.3) 52 (62.7)
ndocrine therapy .004 *
Yes 67 (55.8) 53 (44.2)
No 28 (35.0) 52 (65.0)
R, androgen receptor; ER, estrogen receptor; PR, progesterone receptor; pAkt, phosphorylated
kt; pPTEN, phosphorylated phosphatase and tensin homolog; HER2, human epidermal growth
ctor receptor type 2.
* Statistically significant.
** Fisher exact test.T
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faAR expression and survival. Women with AR-expressing or
positive tumors had significantly higher OS (mean OS = 10.2 ±
0.465 years) than women whose tumors did not express AR (mean
OS = 5.8 ± 0.348 years) (P = .042; Figure 2A). Lymph node
involvement showed a significant (P = .043) association with lower
OS. Patients with large tumor size (P = .069) and positive pAkt status
(P = .243) tended to also have decreased OS (Table 3).
3.4.2. Relationship between AR/ER expression and survival. To
compare the potential prognostic value of AR and ER coexpression
on survival, patients were categorized into the following four
groups: 1) AR+/ER+ (n = 19), 2) AR+/ER− (n = 16), 3) AR−/ER+
(n = 10), and 4) AR−/ER− (n = 37). Although survival analyses
showed no significant OS difference among the four groups (P = .214),
women with AR+/ER+ tumors showed a trend for a better OS
(mean OS = 5.0 ± 0.257 years) compared to the AR −/ER+
(mean OS = 4.4 ± 0.573 years) subgroup. We also found a survival
advantage of AR expression in the AR+/ER− group with only 12.5%
deaths (2 of 16), compared to 27% (10 of 37) deaths in patients with
AR−/ER− tumors (P = .214; Figure 2B).
AR expression, endocrine therapy, and survival. The association of
AR expression with OS in the subgroup of patients receiving
endocrine therapy was investigated (n = 26). In this subgroup,
patients with AR-positive tumor showed significantly better OS
compared to patients whose tumors did not express AR (P = .020;
Figure 2C).
Relationship between AR/pPTEN expression and survival. To
compare the potential prognostic impact of AR and pPTEN coexpression
on survival, patients were categorized into the following four groups: 1)
AR+/pPTEN+ (n = 14), 2) AR+/pPTEN− (n = 20), 3) AR−/pPTEN+
(n = 22), and 4) AR−/pPTEN− (n = 16). Although survival analyses
showed that there was no significant OS difference among the four
groups (P = .289), women with AR+/pPTEN+ tumors had better
survival with only 7.1% deaths (1 of 14), compared to 32%
deaths (5 of 16) in the AR−/pPTEN− group of patients with
BCa. We also found a survival benefit of AR expression in the
AR+/pPTEN− group with only 10% deaths (2 of 20), compared
to 22.7% deaths in the group of patients with AR−/pPTEN +
tumors (5 of 22) (P = .289; Figure 2D).
Relationship between AR/pAkt expression and survival. The
association of AR with OS in pAkt-positive patients (n = 58) was
determined, and we found that patients whose tumors expressed both
pAkt and AR (AR+/pAkt+) had better OS compared to women with
AR−/pAkt+ tumors (P = .037; Figure 2E).
Relationship of AR with pAkt+/pPTEN− combinatorial groups
and survival. The implications of AR expression on disease
outcome were assessed in pAkt+/pPTEN− (n = 31) tumors.
Although survival analyses showed that there was no significant
OS difference between patients with AR+/pAkt+/pPTEN− (n = 18)
and AR−/pAkt+/pPTEN− (n = 13) tumors (P = .114), women with
AR+/pAkt+/pPTEN− tumors had relatively higher OS (mean OS =
7.1 ± 0.535 years;) compared to women with AR−/pAkt+/pPTEN−
tumors (mean OS = 5.1 ± 0.738 years) (Figure 2F).Discussion
The expression of AR in this study, as determined by immunohis-
tochemistry, demonstrated that 47.5% (95 of 200) of invasive BCa
tumors, from a Pakistani cohort, expressed nuclear AR. This is similar
to other reported studies, where the percentage of AR-positive tumors
Figure 2. Kaplan-Meier curves compare OS stratified by (A) expression of AR in all patients with BCa, (B) expression of AR/ER, (C) expression
of AR in patients receiving endocrine therapy, (D) expression of AR/pPTEN, (E) expression of AR in patients with pAkt-positive tumors, and
(F) in patients with combinatorial status of pAkt-positive/pPTEN-negative tumor.
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genuine biologic variations, arising due to environmental and genetic
diversity across the globe.
In the current study, tumors that expressed AR were of low or
intermediate grade (grades I and II) and expressed ER and PR, whichis consistent with previous studies [11,33]. We also found that AR
expression in tumors was significantly associated with longer OS, with
a survival advantage of 4.4 years, in comparison to women whose
tumors did not express AR. Our data are consistent with previous
studies that have assessed AR expression in BCa and its potential as an
Table 3. Survival Analysis (Kaplan-Meier and log-rank test) and Significance of AR, pAkt, Tumor
Size, Grade, and Node Involvement.
Factors N Mean OS in Years (±SE) P Value
AR .042 *
Negative 47 5.8 (±0.35)
Positive 35 10.2 (±0.46)
pAkt .243
Negative 14 10.4 (±0.57)
Positive 58 6.7 (±0.33)
Tumor size .069
T1 and T2 66 9.6 (±0.42)
T3 and T4 13 4.9 (±0.54)
Grade .566
I and II 45 7.8 (±0.42)
III 35 9.0 (±0.625)
Node involvement .043 *
N0 44 9.5 (±0.53)
N1 20 8.6 (±0.40)
N2 8 4.7 (±0.68)
N3 8 3.9 (±0.52)
* Statistically significant; N, number of patients; SE, standard error.
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showed that expression of AR in breast tumors emerges as an
indicator of better survival [12]. We found a significant association
between lymph node involvement and poor survival, whereas factors
including age, HER2 status, ER, PR, and tumor size demonstrated no
association with prognosis. To our knowledge, this is the first study
that demonstrates a potential prognostic value of AR expression in
Pakistani women who have been diagnosed with invasive BCa.
We further analyzed the prognostic significance of AR in patients
who were stratified by ER status. Our analysis showed that patients
with AR+/ER+ tumors had better OS compared to the group that was
AR−/ER+. We also found that patients with ER-negative tumors
expressing AR (AR+/ER−) had a better survival than patients with
AR−/ER− tumors. However, despite displaying a positive trend of AR
expression with survival, a significant association could not be
ascribed in AR/ER subgroup analysis, and we would cautiously
attribute this to the small sample size and low number of deaths.
Previous studies suggest that AR expression is associated with
improved survival among women with ER-positive tumors [42,43].
Data supporting this assertion are based on an in vitro study that
showed that AR interacted with estrogen-responsive elements on the
ER gene and inhibited ER-mediated growth of BCa cells [44]. The
role of AR in patients with ER-negative tumors has not been fully
elucidated as only a few studies have examined AR’s role in these
patients [36,45]. There is inconsistency in studies examining AR
expression in ER-negative BCa. Peters et al. found no association,
whereas Agoff et al. found an association of AR expression with
improved survival in patients with ER-negative tumors [45].
Expression of ER in tumors holds considerable value for the
prediction of response to endocrine therapy [46], whereas only 50%
of ER-positive tumors respond to endocrine therapies [47,48]. To
date, clinical benefits of AR expression in patients receiving endocrine
therapy have not been exhaustively studied [49]. In our study,
patients with AR+/ER+ tumors, receiving endocrine therapy, showed
improved survival, compared to patients whose tumors were AR−/
ER+. These results suggest that AR expression increased the
sensitivity of tumors to endocrine therapy and AR negativity could
possibly be associated with decreased response to endocrine therapy.
Previously, Park et al. demonstrated AR as a marker for better
response to endocrine treatment in ER-positive tumors [50].Additionally, an in vitro study has found that aromatase inhibitors
have a greater antiproliferative effect on AR+/ER+ BCa cell line. The
inhibitory effect may have been due to inhibition of estrogen
synthesis and activation of the intracellular AR signaling, caused by
sustained androgen levels [51]. Taken together, these findings suggest
that AR expression could be an additional significant marker for
endocrine responsiveness in ER-positive cancers.
Role of PTEN as a negative regulator of Akt signaling pathway is
well recognized, and these two variables are found to be inversely
related with each other [52,53]. To date, little is known about the
AR-mediated regulation of Akt and PTEN expression. Therefore,
we determined AR status along with pAkt and pPTEN in the same
cohort of patients with BCa and analyzed the potential prognostic
significance of AR in patients stratified by pAkt and pPTEN status.
We found expression of pAkt and pPTEN in 81.3% and 50.6% of
invasive BCa, respectively. We did not find independent
association of pAkt or pPTEN expression with any clinicopatho-
logic characteristics or survival, which is in contrast to previous
studies showing association of activated Akt and loss of PTEN with
poor survival [30,37]. Absence of independent prognostic
significance of pAkt and pPTEN in our study could be due to the
ethnic background of the patient population and/or the number of
patients studied.
To date, a very limited number of studies have examined the
expression of AR/Akt/PTEN and their association or cross talk in
BCas. Wang et al. reported positive correlation between AR and
PTEN expression in BCa tissues [27]. Aleskandarany et al. also
demonstrated a direct correlation of pAkt expression with AR status
in invasive BCa [34]. Conversely, Lin et al. described an inverse
relationship between Akt and AR signaling pathways, indicating that
Akt inactivates AR [54] and promotes AR degradation [55] that
resulted in suppression of AR-induced apoptosis. A few in vitro
studies showing the related role of Akt, PTEN, and AR in BCa
suggest that AR lowers Akt activity and increases PTEN expression
that in turn decreases BCa cell proliferation [27,28]. Collectively,
these studies suggest that PTEN-Akt is a complex signaling pathway,
operated under multiple levels of feedback; AR pathway is known to
be involved in this feedback loop and has been shown to
downregulate Akt and upregulate PTEN expression.
Unlike previous studies, we did not find any association between
expression of pAkt and pPTEN with AR status. This suggests
presence of mechanisms other than AR that might be responsible for
regulating Akt/PTEN expression. However, we found that expression
of AR was associated with significantly longer OS in patients with
pAkt-positive tumors, suggesting protective role of AR in these
patients. We also found a survival advantage with only 7.1% deaths in
patients with AR+/pPTEN+ tumors, whereas loss of expression of
both markers was found to be associated with lower OS with 32%
deaths. These results suggest that AR-PTEN coexpression might be
decreasing the cellular proliferation and increasing apoptosis (action
mediated by pAkt), resulting in increased OS in the subset of patients
with AR+/pPTEN+ tumors.
Reportedly, patients with Akt+ and PTEN− tumors have been
shown to exhibit worst survival; however, these patients were not
stratified into AR-positive and AR-negative groups [31]. We stratified
tumors in context of combined expression of pAkt and pPTEN and
determined the impact of AR expression on survival in patients with
pAkt+/pPTEN− tumors. We found that, in a subset of women with
pAkt+/pPTEN− tumors, expression of AR conferred a survival
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suggest that AR, independent of its coexpression with pPTEN, could
be negatively regulating Akt-mediated proliferative effect as shown by
survival advantage of 2 years in patients with AR+/pAkt+/pPTEN−
tumors when compared with AR−/pAkt+/pPTEN− tumors. This did
not reach to statistical significance possibly due to low number of
patients (n = 31) in this subset (Figure 2D). The mechanism of these
important observations where AR appears to negate the proliferative
and antiapoptotic effect due to activation of Akt and loss of PTEN,
respectively, warrants further study.
In the current study, survival analysis was limited to patients who
went through a follow-up of 5 years or more (n = 82). A distinctly
better survival was observed not only in patients with AR expression
for whom we had 5-year follow-up but also in patients whose follow-
up was between 2 to 11 years (n = 200, data not shown). However,
relatively small number of deaths (n = 16) restricted us to perform
multivariable analysis.
In conclusion, we found that, in a cohort of Pakistani women with
BCa, expression of AR conferred a survival advantage independent of
other markers. Furthermore, expression of AR in pAkt+/pPTEN−
subgroup could be useful in distinguishing BCa with more favorable
prognosis. Future studies on larger cohort of patients would be
helpful in establishing the role of AR, pAkt, and pPTEN expression as
significant independent prognostic and predictive factors in patients
with BCa.
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